Zusammenfassung
Für die Diagnostik und das therapeutisches Management der Gicht wurden in den vergangenen
Jahren von amerikanischen und europäischen Expertengremien evidenzbasierte Empfehlungen
veröffentlicht, die zu Standardisierung und Qualitätsverbesserung beitragen. In dieser
Übersichtsarbeit werden diese Empfehlungen vorgestellt und diskutiert. Darüber hinaus
werden neue, noch in Entwicklung befindliche Therapieansätze zur Harnsäuresenkung
vorgestellt.
Abstract
Diagnostic procedures and therapy for gout have been the subject of various evidence-based
recommendations published by American and European expert groups in recent years.
These recommendations, contributing to the standardisation and quality improvement
of gout management, are presented and discussed in this review article. In addition,
new developments in therapeutic approaches for hyperuricemia will be introduced.
Schlüsselwörter
Gicht - Diagnose - Therapie - Harnsäuresenkung
Key words
Gout - diagnosis - therapy - hyperuricemia
Literatur
- 1
Nuki G, Simkin P A.
A concise history of gout and hyperuricemia and their treatment.
Arthritis Res Ther.
2006;
8 (Suppl 1)
S1
- 2
Choi H.
Epidemiology of crystal arthropathy.
Rheum Dis Clin N Am.
2006;
32
255-273
- 3
Saag K G, Choi H.
Epidemiology, risk factors, and lifestyle modifications for gout.
Arthritis Res Ther.
2006;
8 (Suppl 1)
S2
- 4
De Souza A WS, Fernandes V, Ferrari A JL.
Female gout: clinical and laboratory features.
J Rheum.
2005;
32
2186-2188
- 5
Mikuis T R, Farrar J T, Bilker W B. et al .
Gout epidemiology: results from the UK General Practice Research Database, 1990 -
1999.
Ann Rheum Dis.
2005;
64
267-272
- 6
Mikuls T R, MacLean C H, Olivieri J. et al .
Quality of care indicators for gout management.
Arthritis Rheum.
2004;
50
937-943
- 7
Mikuls T R, Farrar J T, Bilker W B. et al .
Suboptimal physician adherence to quality indicators for the management of gout and
asymptomatic hyperuricaemia: result from the UK General Practice Research Database
(GPRD).
Rheumatology.
2005;
44
1038-1042
- 8
Borstad G C, Bryant L R, Abel M P. et al .
Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic
gouty arthritis.
J Rheumatol.
2004;
31
2429-2432
- 9
Zhang W, Doherty M, Pascual E. et al .
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task
force of the standing committee for international clinical studies including therapeutics
(ESCISIT).
Ann Rheum Dis online 10.1136/ard.2006.055251.
2006;
- 10
Zhang W, Doherty M, Bardin T. et al .
EULAR evidence based recommendations for gout. Part II: Management. Report of a task
force of the standing committee for international clinical studies including therapeutics
(ESCISIT).
Ann Rheum Dis online 10.1136/ard.2006.055269.
2006;
- 11
Alappatt C, Clayburne G, Schumacher H R.
Concomitant polyarticular septic and gouty arthritis.
J Rheumatol.
2006;
33
1707-1708
- 12
Becker M A, Schumacher H R, Wortmann R L. et al .
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
New Engl J Med.
2005;
353
2450-2461
- 13
Moolenburgh J D, Reinders M K, Jansen T LTA.
Rasburicase treatment in severe tophaceous gout: a novel therapeutic option.
Clin Rheumatol.
2006;
25
749-752
- 14
Ganson N J, Kelly S J, Scarlett E. et al .
Control of hyperuricemia in subjects with refractory gout, and induction of antibody
against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated
urate oxidase.
Arthritis Res Ther.
2006;
8
R12
- 15
Huang H Y, Appel L J, Choi M J. et al .
The effects of vitamin C supplementation on serum concentrations of uric acid.
Arthritis Rheum.
2005;
52
1843-1847
B. Manger
Medizinische Klinik III, Universität Erlangen, Abt. Rheumatologie
Krankenhausstr. 12
91054 Erlangen
Telefon: 0 91 31/8 53 20 75
Fax: 0 91 31/8 53 20 78
eMail: Bernhard.Manger@med3.imed.uni-erlangen.de
